Role of B cells in systemic lupus erythematosus and rheumatoid arthritis

Current Opinion in Immunology

Volumn 20, Issue 6, 2008, Pages 639-645

  Mandik Nayak, Laura ^a   Ridge, Natalie ^a,b   Fields, Michele ^c   Park, Audrey Y ^c   Erikson, Jan ^c  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SAINT JOSEPH S UNIVERSITY   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BORTEZOMIB; RITUXIMAB;

ANTIBODY PRODUCTION; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CLINICAL TRIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; CLONAL DELETION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, B-CELL; SELF TOLERANCE;

EID: 56349097625     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.08.003     Document Type: Review

References (59)

1. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 28 (2008) 18-28. This is an outstanding comprehensive review that incorporates many of the seminal contributions from the author's lab with work from others to generate well-reasoned models for B cell tolerance and activation.
2. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., and Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 301 (2003) 1374-1377
3. Fields M.L., Hondowicz B.D., Wharton G.N., Adair B.S., Metzgar M.H., Alexander S.T., Caton A.J., and Erikson J. The regulation and activation of lupus-associated B cells. Immunol Rev 204 (2005) 165-183
4. Cambier J.C., Gauld S.B., Merrell K.T., and Vilen B.J. B-cell anergy: from transgenic models to naturally occurring anergic B cells?. Nat Rev Immunol 7 (2007) 633-643
5. Herlands R.A., William J., Hershberg U., and Shlomchik M.J. Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur J Immunol 37 (2007) 3339-3351
6. Huang H., Kearney J.F., Grusby M.J., Benoist C., and Mathis D. Induction of tolerance in arthritogenic B cells with receptors of differing affinity for self-antigen. Proc Natl Acad Sci U S A 103 (2006) 3734-3739
7. Mandik-Nayak L., Racz J., Sleckman B.P., and Allen P.M. Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J Exp Med 203 (2006) 1985-1998
8. Samuels J., Ng Y.S., Coupillaud C., Paget D., and Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 201 (2005) 1659-1667
9. Yurasov S., Tiller T., Tsuiji M., Velinzon K., Pascual V., Wardemann H., and Nussenzweig M.C. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 203 (2006) 2255-2261. This paper provides evidence that SLE patients have defects in censoring self-reactive B cells early in development.
10. Fields M.L., Nish S.A., Hondowicz B.D., Metzgar M.H., Wharton G.N., Caton A.J., and Erikson J. The influence of effector T cells and Fas ligand on lupus-associated B cells. J Immunol 175 (2005) 104-111
11. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., Yi J., Guentert T., Tousson A., Stanus A.L., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9 (2008) 166-175
12. Yu D., Tan A.H., Hu X., Athanasopoulos V., Simpson N., Silva D.G., Hutloff A., Giles K.M., Leedman P.J., Lam K.P., et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 450 (2007) 299-303. This study determines the mechanism behind the striking autoimmune phenotype of the sanroque mice. Mice with mutant Roquin show defects in the degradation of the inducible T cell costimulator (ICOS) messenger RNA, which results in excessive T follicular cells and germinal centers as well as autoantibodies and SLE-like pathology.
13. Hondowicz B.D., Fields M.L., Nish S.A., Larkin III J., Caton A.J., and Erikson J. Autoantibody production in lpr/lpr gld/gld mice reflects accumulation of CD4+ effector cells that are resistant to regulatory T cell activity. J Autoimmun 31 (2008) 98-109
14. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6 (2006) 823-835. This is an excellent review that not only includes the major broad conceptual advances but also the corresponding experimental details, particularly with regard to mouse models carrying aberrant TLRs.
15. Fields M.L., Metzgar M.H., Hondowicz B.D., Kang S.A., Alexander S.T., Hazard K.D., Hsu A.C., Du Y.Z., Prak E.L., Monestier M., et al. Exogenous and endogenous TLR ligands activate anti-chromatin and polyreactive B cells. J Immunol 176 (2006) 6491-6502
16. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8 (2008) 34-47
17. Brownlie R.J., Lawlor K.E., Niederer H.A., Cutler A.J., Xiang Z., Clatworthy M.R., Floto R.A., Greaves D.R., Lyons P.A., and Smith K.G. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med 205 (2008) 883-895. In this study, the authors established a number of mouse lines expressing modest increases of the inhibitory receptor FcγRIIb directed either to B cells or macrophages and showed that overexpression on B cells suppresses CIA and SLE while preserving the ability to mount a protective response against bacterial infection.
18. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., Walker E.U., Manz R.A., Tarlinton D.M., and Smith K.G. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 8 (2007) 419-429
19. Mackay M., Stanevsky A., Wang T., Aranow C., Li M., Koenig S., Ravetch J.V., and Diamond B. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 203 (2006) 2157-2164
20. Su K., Yang H., Li X., Li X., Gibson A.W., Cafardi J.M., Zhou T., Edberg J.C., and Kimberly R.P. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 178 (2007) 3272-3280
21. Hoyer B.F., Moser K., Hauser A.E., Peddinghaus A., Voigt C., Eilat D., Radbruch A., Hiepe F., and Manz R.A. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199 (2004) 1577-1584
22. William J., Euler C., and Shlomchik M.J. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 174 (2005) 6879-6887
23. Cappione III A., Anolik J.H., Pugh-Bernard A., Barnard J., Dutcher P., Silverman G., and Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115 (2005) 3205-3216
24. Rowley M.J., Nandakumar K.S., and Holmdahl R. The role of collagen antibodies in mediating arthritis. Mod Rheumatol 18 (2008) 429-441
25. Steiner G., and Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 4 Suppl. 2 (2002) S1-5
26. Monach P., Hattori K., Huang H., Hyatt E., Morse J., Nguyen L., Ortiz-Lopez A., Wu H.J., Mathis D., and Benoist C. The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med 136 (2007) 269-282
27. van Gaalen F., Ioan-Facsinay A., Huizinga T.W., and Toes R.E. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol 175 (2005) 5575-5580
28. Chapuy-Regaud S., Sebbag M., Baeten D., Clavel C., Foulquier C., De Keyser F., and Serre G. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol 174 (2005) 5057-5064
29. Masson-Bessiere C., Sebbag M., Girbal-Neuhauser E., Nogueira L., Vincent C., Senshu T., and Serre G. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166 (2001) 4177-4184
30. Reparon-Schuijt C.C., van Esch W.J., van Kooten C., Schellekens G.A., de Jong B.A., van Venrooij W.J., Breedveld F.C., and Verweij C.L. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 44 (2001) 41-47
31. Papadopoulos N.G., Tsiaousis G.Z., Pavlitou-Tsiontsi A., Giannakou A., and Galanopoulou V.K. Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients?. Clin Rev Allergy Immunol 34 (2008) 11-15
32. de Vries-Bouwstra J.K., Goekoop-Ruiterman Y.P., Verpoort K.N., Schreuder G.M., Ewals J.A., Terwiel J.P., Ronday H.K., Kerstens P.J., Toes R.E., de Vries R.R., et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58 (2008) 1293-1298
33. Korganow A.S., Ji H., Mangialaio S., Duchatelle V., Pelanda R., Martin T., Degott C., Kikutani H., Rajewsky K., Pasquali J.L., et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10 (1999) 451-461
34. Kuhn K.A., Kulik L., Tomooka B., Braschler K.J., Arend W.P., Robinson W.H., and Holers V.M. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116 (2006) 961-973
35. Taneja V., Krco C.J., Behrens M.D., Luthra H.S., Griffiths M.M., and David C.S. B cells are important as antigen presenting cells for induction of MHC-restricted arthritis in transgenic mice. Mol Immunol 44 (2007) 2988-2996
36. O'Neill S.K., Shlomchik M.J., Glant T.T., Cao Y., Doodes P.D., and Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 174 (2005) 3781-3788
37. Takemura S., Braun A., Crowson C., Kurtin P.J., Cofield R.H., O'Fallon W.M., Goronzy J.J., and Weyand C.M. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167 (2001) 1072-1080
38. Lund F.E. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 20 (2008) 332-338. In this article, the authors review the current literature describing both the pro-inflammatory and regulatory cytokines produced by B cells.
39. Fillatreau S., Gray D., and Anderton S.M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 8 (2008) 391-397
40. Mauri C., Gray D., Mushtaq N., and Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197 (2003) 489-501
41. Mauri C., and Ehrenstein M.R. The 'short' history of regulatory B cells. Trends Immunol 29 (2008) 34-40
42. Evans J.G., Chavez-Rueda K.A., Eddaoudi A., Meyer-Bahlburg A., Rawlings D.J., Ehrenstein M.R., and Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 178 (2007) 7868-7878
43. Cambridge G., Stohl W., Leandro M.J., Migone T.S., Hilbert D.M., and Edwards J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54 (2006) 723-732
44. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 (2008) 676-688
45. Sabahi R., and Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66 (2006) 1933-1948
46. Sutter J.A., Kwan-Morley J., Dunham J., Du Y.Z., Kamoun M., Albert D., Eisenberg R.A., and Luning Prak E.T. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 126 (2008) 282-290
47. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., Lin W.Y., Hu Z., Lu Y., Chen Y., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
48. Bouaziz J.D., Yanaba K., Venturi G.M., Wang Y., Tisch R.M., Poe J.C., and Tedder T.F. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A 104 (2007) 20878-20883
49. Hamel K., Doodes P., Cao Y., Wang Y., Martinson J., Dunn R., Kehry M.R., Farkas B., and Finnegan A. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol 180 (2008) 4994-5003
50. Ahuja A., Shupe J., Dunn R., Kashgarian M., Kehry M.R., and Shlomchik M.J. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179 (2007) 3351-3361
51. Ahuja A., Anderson S.M., Khalil A., and Shlomchik M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 105 (2008) 4802-4807
52. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., Wiethe C., Winkler T.H., Kalden J.R., Manz R.A., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14 (2008) 748-755. An exciting new approach to target plasma cells is presented.
53. Mackay F., and Cancro M.P. Travelling with the BAFF/BLyS family: are we there yet?. Semin Immunol 18 (2006) 261-262
54. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., and Cyster J.G. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20 (2004) 441-453
55. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., and Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 (2004) 785-798
56. Hondowicz B.D., Alexander S.T., Quinn III W.J., Pagan A.J., Metzgar M.H., Cancro M.P., and Erikson J. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol 19 (2007) 465-475
57. Benson M.J., Dillon S.R., Castigli E., Geha R.S., Xu S., Lam K.P., and Noelle R.J. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180 (2008) 3655-3659
58. Tiller T., Tsuiji M., Yurasov S., Velinzon K., Nussenzweig M.C., and Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity 26 (2007) 205-213
59. Koelsch K., Zheng N.Y., Zhang Q., Duty A., Helms C., Mathias M.D., Jared M., Smith K., Capra J.D., and Wilson P.C. Mature B cells class switched to IgD are autoreactive in healthy individuals. J Clin Invest 117 (2007) 1558-1565